Literature DB >> 9240498

Apheresis therapy for prolonged red cell aplasia after major ABO-mismatched bone marrow transplantation.

S Ohta1, H Yokoyama, T Ise, K Takasawa, T Wada, S Nakao, T Matsuda, K Kobayashi.   

Abstract

Two cases of leukemia were treated successfully with apheresis for delayed recovery of erythropoiesis due to antibody-mediated red cell aplasia after ABO-mismatched bone marrow transplantation (BMT). A 25-year-old female (ABO group O) underwent BMT from her brother (group A). Immunoadsorption using Biosynsorb A performed on day 146 after BMT followed by double filtration plasma pheresis (DFPP) reduced anti-A antibody titers from 1:32 to 1:2. Anemia improved dramatically within 2 weeks. A 49-year-old female (group O) underwent BMT from her mother (group A). She was treated with DFPP on day 131 after BMT. Anti-A antibody titers dropped from 1:16 to 1:1 and anemia improved gradually.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9240498     DOI： 10.2169/internalmedicine.36.487

Source DB:  PubMed          Journal:  Intern Med        ISSN： 0918-2918            Impact factor:   1.271


  4 in total

Review 1.  Pure red cell aplasia after major or bidirectional ABO incompatible hematopoietic stem cell transplantation: to treat or not to treat, that is the question.

Authors:  Javier Marco-Ayala; Inés Gómez-Seguí; Guillermo Sanz; Pilar Solves
Journal:  Bone Marrow Transplant       Date:  2020-11-14       Impact factor: 5.483

2.  Prevention of pure red cell aplasia after major or bidirectional ABO blood group incompatible hematopoietic stem cell transplantation by pretransplant reduction of host anti-donor isoagglutinins.

Authors:  Georg Stussi; Jörg Halter; Eveline Bucheli; Piero V Valli; Lutz Seebach; Jürg Gmür; Alois Gratwohl; Urs Schanz; Jakob R Passweg; Jörg D Seebach
Journal:  Haematologica       Date:  2009-01-14       Impact factor: 9.941

3.  Fludarabine- and cyclophosphamide-based nonmyeloablative conditioning regimen for transplantation of chronic granulomatous disease: possible correlation with prolonged pure red cell aplasia.

Authors:  Tohru Fujiwara; Minami Yamada; Koichi Miyamura; Yasuo Tomiya; Kenichi Ishizawa; Hideo Harigae; Junichi Kameoka; Masayoshi Minegishi; Shigeru Tsuchiya; Takeshi Sasaki
Journal:  Int J Hematol       Date:  2004-04       Impact factor: 2.490

4.  Successful Treatment of Pure Red Cell Aplasia with Rituximab in Patients after ABO-Compatible Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Sung-Hoon Jung; Jae-Sook Ahn; Deok-Hwan Yang; Hyung Chul Park; Soo-Young Bae; Yeo-Kyeoung Kim; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  Case Rep Oncol       Date:  2012-02-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.